Spots Global Cancer Trial Database for locally advanced or metastatic
Every month we try and update this database with for locally advanced or metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | NCT00607438 | Breast Cancer | Paclitaxel Albu... Sorafenib (Nexa... | 18 Years - | Veeda Oncology | |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01357330 | Solid Tumors | SAR245408 (XL14... MSC1936369B | 18 Years - | Sanofi | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | NCT04465734 | Hepatocellular ... | HLX10 HLX04 Sorafenib | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | NCT00607438 | Breast Cancer | Paclitaxel Albu... Sorafenib (Nexa... | 18 Years - | Veeda Oncology | |
| Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. | NCT05937906 | Non-Small Cell ... | Phase I - Mirda... Phase II - Mird... Phase I - Mirda... Phase I - Mirda... Phase I - Mirda... | 18 Years - | Centre Georges Francois Leclerc | |
| A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | NCT04033354 | Squamous Non Sm... | HLX10 carboplatin and... Placebo | 18 Years - | Shanghai Henlius Biotech | |
| Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. | NCT05937906 | Non-Small Cell ... | Phase I - Mirda... Phase II - Mird... Phase I - Mirda... Phase I - Mirda... Phase I - Mirda... | 18 Years - | Centre Georges Francois Leclerc | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | NCT06005974 | AXIN1 Gene Muta... APC Gene Mutati... Solid Tumor | REC-4881 | 55 Years - | Recursion Pharmaceuticals Inc. | |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | NCT03127098 | Thyroid Cancer Colon Cancer Ovarian Cancer Breast Cancer Lung Cancer Pancreatic Canc... | ETBX-011 ALT-803 | 21 Years - | NantCell, Inc. | |
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | NCT00607438 | Breast Cancer | Paclitaxel Albu... Sorafenib (Nexa... | 18 Years - | Veeda Oncology | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative | NCT02754011 | Breast Cancer | Combination of ... | 18 Years - | UNICANCER | |
| Stromal TARgeting for PAncreatic Cancer (STAR_PAC) | NCT03307148 | Pancreatic Aden... | ATRA Gemcitabine Nab-paclitaxel | 18 Years - | Barts & The London NHS Trust | |
| Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure | NCT04193553 | Gastro Intestin... | Lenvatinib Placebo Best supportive... | 18 Years - | Centre Leon Berard |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
